Are apixaban and rivaroxaban distributed into human breast milk to clinically relevant concentrations?

Blood. 2020 Oct 8;136(15):1783-1785. doi: 10.1182/blood.2020006231.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Monitoring
  • Factor Xa Inhibitors / adverse effects*
  • Factor Xa Inhibitors / pharmacokinetics*
  • Factor Xa Inhibitors / therapeutic use
  • Female
  • Humans
  • Milk, Human*
  • Postpartum Period
  • Pyrazoles / adverse effects*
  • Pyrazoles / pharmacokinetics*
  • Pyrazoles / therapeutic use
  • Pyridones / adverse effects*
  • Pyridones / pharmacokinetics*
  • Pyridones / therapeutic use
  • Rivaroxaban / adverse effects*
  • Rivaroxaban / pharmacokinetics*
  • Rivaroxaban / therapeutic use
  • Time Factors
  • Venous Thromboembolism / etiology
  • Venous Thromboembolism / prevention & control

Substances

  • Factor Xa Inhibitors
  • Pyrazoles
  • Pyridones
  • apixaban
  • Rivaroxaban